Who is your solution to and how does it meet a specific need for women?
Marcel Marist: Our Ostaat ™ technology targets women above all, and it’s no coincidence. Osteoporosis affects 80 % of women, especially after menopause, when the fall in estrogens accelerates bone loss. One out of two over the age of 50 will have a fracture linked to this disease, often with heavy consequences on mobility and autonomy. However, a large part of them refuses or abandons conventional treatments, often because of side effects. This is where our solution comes in: non -drug, non -invasive, integrated into intelligent clothing, it allows you to act in prevention, gently. We want to give women the power to protect their bone health, without compromise on their quality of life.
Can you present your solution to us in detail?
Ostaat ™, an acronym for one stimulation at a time, is a medical technology on board intelligent shorts. It incorporates flexible polymer electrodes and a miniature electrical stimulation generator, almost imperceptible for the user. By emitting slight targeted pulses on hips – a particularly at risk area – the system naturally stimulates bone cells to strengthen their density. In ten weeks, our preclinical trials have already shown bone growth of 2 %, without any medication*. Our solution is particularly aimed at postmenopausal women, often excluded from current solutions, and offers a comfortable, discreet and efficient response. It is a new path in the prevention of fragility fractures.
What are the next steps for Ostaat ™?
We are at a pivotal moment. We are currently finalizing a fundraising of $ 1.5 million to accelerate development. The final prototype of our intelligent shorts is almost ready for a first clinical study, which will start in Tunisia with Dr. Ramzi Bouzidi. In parallel, we prepare the regulatory procedures for the North American and European markets. Our ambition is clear: to offer a solution reimbursed by health systems, by relying on robust clinical data. We also structure our production with Canadian partners and work on a launch strategy that combines health and well-being. And of course, we continue to strengthen our visibility with clinical and distributors. The path is traced, and the potential impact is immense.